Are Itrovance (itraconazole) and Conazit (itraconazole) therapeutically equivalent oral azole antifungals, and how should I choose between them?

Itrovance and Conazit Are NOT Therapeutically Equivalent Products

Based on FDA labeling, Itrovance and Conazit are fundamentally different products that cannot be used interchangeably. These are not different brand names for the same itraconazole formulation—they have distinct indications, contraindications, and patient populations.

Critical Differences Between Products

Itrovance (Itraconazole)

• Indication: Systemic antifungal for invasive and superficial mycoses 1
• Patient population: Adults and children over 12 years 1
• Duration guidance: Discontinue if symptoms persist >7 days or recur 1
• Route: Oral systemic absorption 1

Conazit (Topical Antifungal)

• Indication: Topical use only, NOT for systemic infections 1
• Contraindications: Cannot be used on wounds or damaged skin 1
• Age restriction: Not for children under 12 years 1
• Route: Topical application only 1

Clinical Decision Algorithm

For systemic fungal infections (onychomycosis, candidiasis, aspergillosis):

• Use itraconazole oral formulations (Itrovance if available) 2
• Never substitute with topical products like Conazit 1

For dermatophyte onychomycosis specifically:

• First-line: Terbinafine 250 mg daily (6 weeks fingernails, 12-16 weeks toenails) due to superior efficacy (55% complete cure vs 26% with itraconazole pulse therapy) 2
• Second-line: Itraconazole 200 mg daily × 12 weeks continuous OR 400 mg daily × 1 week/month pulse therapy (2 pulses for fingernails, 3 pulses for toenails) 2

For Candida onychomycosis:

• First-line: Itraconazole (92% cure rate with pulse therapy) over terbinafine (40% cure rate with pulse therapy) 2
• Minimum duration: 4 weeks for fingernails, 12 weeks for toenails 2

Itraconazole Formulation Considerations

When prescribing itraconazole (regardless of brand name), formulation matters critically 3, 4:

• Oral solution: Superior bioavailability compared to capsules, especially in patients with achlorhydria, HIV, or neutropenia 3, 4, 5
• Capsules: Require acidic gastric pH for absorption; avoid with H2-blockers, PPIs, or antacids 6
• Administration: Take capsules with food to enhance absorption 6

Monitoring Requirements for Systemic Itraconazole

Baseline assessment 2:

• Liver function tests (AST, ALT, bilirubin)
• Complete blood count
• Renal function

During therapy 2:

• Monitor LFTs if treatment >21 days
• Therapeutic drug monitoring recommended for serious infections 7
• Target trough levels: 0.5-1.0 mg/L for prophylaxis, >1.0 mg/L for treatment 7

Critical Drug Interactions

Itraconazole is a potent CYP3A4 inhibitor 2, 8:

• Increases levels of: vincristine, cyclosporine (requires 50-55% dose reduction), proteasome inhibitors, tyrosine kinase inhibitors 2, 6
• Decreased by: rifampin, phenytoin, carbamazepine 6
• Stop itraconazole ≥10 days before administering interacting chemotherapy agents 2

Common Pitfalls to Avoid

1. Never assume brand name equivalence without verifying FDA labeling—Conazit is topical only 1
2. Do not use topical products for systemic infections—this represents treatment failure 1
3. Do not interchange itraconazole capsules and solution without dose adjustment—bioavailability differs significantly 3, 4
4. Do not prescribe itraconazole capsules with acid-suppressing medications—absorption will be inadequate 6
5. Do not use itraconazole as first-line for dermatophyte onychomycosis—terbinafine has superior efficacy and lower relapse rates (23% vs 53%) 2